NeurAxis to Present First Quarter 2025 Financial Results
NeurAxis, Inc. (NYSE American: NRXS), a trailblazer in medical technology, is gearing up to share its financial results for the first quarter of 2025. This report will cover the period concluded on March 31, 2025. The eagerly awaited announcement is set to be made on May 12, 2025, just before the market opens, paving the way for an insightful conference call shortly thereafter.
Details of the Conference Call
Scheduled for May 12, 2025, at 9:00 am ET, this conference call promises to be an informative session. Participants can expect to gain a deeper understanding of NeurAxis's performance and strategic direction, as the leadership team discusses the company's financial results and endeavors in neuromodulation therapy.
How to Access the Call
Participants can access the conference call through a live webcast, conveniently located in the Investor Relations section of NeurAxis's website. This platform not only allows attendees to listen in but also provides a portal for submitting questions. Alternatively, those who prefer to join via telephone can do so by registering online to obtain dial-in information and a unique PIN required to join the call.
Replay Availability
For those who cannot attend the live session, a replay will be available on NeurAxis's website. This ensures that everyone has the opportunity to stay informed about the company’s developments and insights regarding its innovative therapies.
About NeurAxis, Inc.
NeurAxis, Inc. is actively engineering new pathways in the realm of medical technology. By focusing on advanced neuromodulation therapies, the company strives to mitigate chronic conditions that plague both children and adults. Central to its mission is the IB-Stim™ therapy, an FDA-cleared proprietary technology that employs Percutaneous Electrical Nerve Field Stimulation (PENFS). This innovative treatment specifically addresses functional abdominal pain linked to irritable bowel syndrome (IBS) in adolescents aged between 8 and 21 years, marking a significant stride in pediatric healthcare.
Clinical Advancements and Future Outlook
NeurAxis is committed to continuous research, with ongoing clinical trials exploring the efficacy of PENFS in various pediatric and adult conditions that currently lack adequate treatment options. This proactive approach not only highlights the company’s dedication to improving patient outcomes but also positions NeurAxis as a forward-thinking leader in medical technology.
Connecting with NeurAxis
Anyone interested in learning more about NeurAxis, its innovative therapies, or the upcoming conference call is encouraged to reach out via their Investor Relations email. The company prioritizes transparency and communication, reinforcing its commitment to both investors and the medical community.
Contact Information
For general inquiries, you can reach NeurAxis at:
Email: info@neuraxis.com
For investor relations, contact:
Ben Shamsian
Lytham Partners
646-829-9701
Email: shamsian@lythampartners.com
Frequently Asked Questions
What is NeurAxis focused on?
NeurAxis focuses on neuromodulation therapies aimed at treating chronic and debilitating conditions affecting both children and adults.
When is the conference call for first quarter results?
The conference call is scheduled for May 12, 2025, at 9:00 am ET.
How can I participate in the conference call?
You can participate by accessing the live webcast on the company’s Investor Relations page or by registering for dial-in access.
What is the IB-Stim™ therapy?
IB-Stim™ therapy is a novel FDA-cleared treatment designed to alleviate functional abdominal pain in adolescents suffering from irritable bowel syndrome (IBS).
Is there a replay available after the call?
Yes, a replay of the conference call will be accessible through NeurAxis's website shortly after the live session concludes.
